CStone Pharmaceuticals WKN: A2PEFW ISIN: KYG2588M1006 Forum: Aktien Thema: Hauptdiskussion

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-completes-hk467-28-million-share-placing-to-boost-rd

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-phase-iii-study-on-cs1001-for-nsclc-a-market-game-changer

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-advances-phase-iii-study-for-liver-cancer-treatment

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-schedules-board-meeting-for-interim-results-review

https://www.cstonepharma.com/en/html/news/3833.html

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-unveils-promising-bispecific-antibody-targets-for-autoimmune-diseases

https://firstwordpharma.com/story/5963396 https://www.google.com/amp/s/simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/exploring-three-high-growth-tech-stocks-in-asia-7/amp

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-unveils-promising-cancer-therapies-at-aacr-2025

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-advances-clinical-trial-for-innovative-cancer-therapy https://fox4kc.com/business/press-releases/cision/20250305CN34134/cstone-submits-clinical-trial-application-in-australia-for-cs5001-ror1-adc-in-combination-with-first-line-standard-of-care-for-dlbcl/ https://www.koreabiomed.com/news/articleView.html?idxno=26847 https://www.clinicaltrialsarena.com/news/cstone-trial-cs2009/

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-strengthens-board-with-new-appointment

https://ch.marketscreener.com/kurs/aktie/CSTONE-PHARMACEUTICALS-57946082/news/CStone-Pharmaceuticals-gibt-die-Einreichung-eines-Antrags-auf-klinische-Prufung-in-Australien-fur-48642816/?utm_medium=RSS&utm_source=googlenews&utm_content=20241223

https://www.tipranks.com/news/company-announcements/cstones-cs5001-advances-in-cancer-treatment-trials https://www.marketscreener.com/quote/stock/CSTONE-PHARMACEUTICALS-57946082/news/CStone-Pharmaceuticals-Announces-First-Patient-Enrollment-in-the-Global-Multicenter-Phase-IB-Clinica-48625399/

Im Moment schon...

Meint ihr das wird noch was? 🙄

Guten Morgen Scholliii, das frage ich mich auch 😅 an sich ist das Unternehmen ja ein super Investment (innovativ , expandierend, immens wichtige Produkte ) . Aber da vermutlich noch ein längerer Weg bis profitabel ist der Kurs schwer enttäuschend. Ich bin dennoch zuversichtlich , was meinst du? LG